Parkinson’s IPS cell trial in Japan switching to allogeneic

Jun-Takahashi

What’s better for stem cell trials such as for vision loss or Parkinson’s Disease: allogeneic or autologous cells? In a major shift earlier this year, the induced pluripotent stem (IPS) cell trial in Japan for treatment of macular degeneration (MD) switched gears from using the patients’ own cells (called “autologous”) to using banked cells from …

Parkinson’s IPS cell trial in Japan switching to allogeneic Read More »